Use of Patient Engagement to Develop and Validate a Novel Patient-Reported Outcome
Source
National Health Council
Link
Patient-Focused Medical Product Development Case Examples
Description of Case Study
Incyte developed and validated a patient-reported outcome (PRO) measure (Myelofibrosis Symptom Assessment Form, version 2.0) through patient input and testing aligned with US Food and Drug Administration (FDA) guidance. The purpose of engagement was to ensure measures reflected patient experience and could support use as a clinical trial endpoint. This case is frequently cited by the FDA as a successful example of clinical outcome assessment development.
Quick Facts Organization name: Incyte Corporation |
Product Type(s)
- pharmaceutical/biological product
Product Medical Specialty Area(s)
- hematology
Stakeholders
- patients and caregivers
- patient organizations
- regulators
Methods and Sources of Patient Input
- interviews/focus groups/surveys
- clinical outcome assessments (PROs, clinician-reported outcomes, observer-reported outcomes)
Impact of Patient Engagement
Through patient engagement activities such as patient interviews, cognitive debriefing, and validation testing, the product developer was able to meet the FDA guidance requirements to use a novel PRO measure as a clinical trial end point.
Reported areas of impact include:
- Development of PRO instrument: Patient input informed the design of a symptom assessment tool.
- Regulatory-aligned validation: Engagement supported development consistent with FDA PRO guidance.
- Use in clinical trials: The PRO was used to measure treatment benefit in trials.